Get the Stockscreener App
0.833
1.61%
0.0132
After Hours:
.83
-0.003
-0.36%
Enlivex Ltd stock is traded at $0.833, with a volume of 272.51K.
It is up +1.61% in the last 24 hours and down -4.65% over the past month.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
See More
Previous Close:
$0.8198
Open:
$0.82
24h Volume:
272.51K
Relative Volume:
0.50
Market Cap:
$200.79M
Revenue:
-
Net Income/Loss:
$1.24B
P/E Ratio:
0.0327
EPS:
25.475
Net Cash Flow:
$-31.80M
1W Performance:
+3.93%
1M Performance:
-4.65%
6M Performance:
-17.52%
1Y Performance:
-24.27%
1-Day Range:
$0.80
$0.8551
1-Week Range:
$0.7946
$0.8986
52-Week Range:
$0.66
$2.10
Enlivex Ltd Stock (ENLV) Company Profile
Compare ENLV vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENLV
Enlivex Ltd
|
0.833 | 197.61M | 0 | 1.24B | -31.80M | 25.48 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Enlivex Ltd Stock (ENLV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-21 | Reiterated | H.C. Wainwright | Buy |
Enlivex Ltd Stock (ENLV) Latest News
Enlivex Ltd. (NASDAQ: ENLV) registers 23.33M shares for resale by noteholder - Stock Titan
Enlivex Ltd Share PriceENLV, RNS News, Articles, Quotes, & Charts (NASDAQ:ENLV) - Proactive financial news
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange - The Manila Times
Enlivex’s $567M RAIN treasury asset gains a new market on HTX - Stock Titan
[EFFECT] Enlivex Ltd. SEC Filing - Stock Titan
Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million - The Manila Times
Enlivex Ltd.: Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million - FinanzNachrichten.de
$567M in RAIN: Enlivex taps option priced 55% below April 27 close - Stock Titan
Enlivex Therapeutics (ENLV) price target decreased by 30.00% to 7.14 - MSN
Enlivex Therapeutics (NASDAQ:ENLV) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Enlivex (ENLV) price target increased by 53.85% to 20.40 - MSN
ENLV (Enlivex Ltd. Ordinary Shares) posts sharply wider Q4 2025 loss than expected, shares drop 3.26% on dismal earnings.Barrier to Entry - Cổng thông tin điện tử Tỉnh Sơn La
Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress - The Manila Times
New knee osteoarthritis data from Enlivex heads to OARSI 2026 - Stock Titan
Enlivex receives Danish approval for knee osteoarthritis trial By Investing.com - Investing.com India
Enlivex Ltd.: Fundamental Analysis and Financial Ratings | ENLV | IL0011319527 - marketscreener.com
Enlivex Ltd. (ENLV) registers 23.3M conversion shares from $21M note - Stock Titan
Enlivex (ENLV) Secures Approval for Phase 2b Osteoarthritis Clin - GuruFocus
Enlivex receives Danish approval for knee osteoarthritis trial - Investing.com
Enlivex Secures Danish Approval for Global Phase 2b Trial of Allocetra in Knee Osteoarthritis - TipRanks
Enlivex (Nasdaq: ENLV) gets second approval for global Phase 2b Allocetra knee OA trial - Stock Titan
Enlivex expands knee arthritis trial from the US into Europe - Stock Titan
H.C. Wainwright Highlight Improved Balance Sheet Supporting Enlivex Ltd. (ENLV) Outlook - Insider Monkey
5 Oversold Biotech Stocks to Invest In Now - Insider Monkey
Shai A Novik Net Worth (2026) - GuruFocus
Gili Hart Net Worth (2026) - GuruFocus
Shachar Shlosberger Net Worth (2026) - GuruFocus
Oren Hershkovitz Net Worth (2026) - GuruFocus
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48 - 富途牛牛
Einat Galamidi Net Worth (2026) - GuruFocus
What are hedge funds doing with Enlivex (ENLV) Stock | Price at $0.80, Down 17.32%Most Discussed Stocks - Cổng thông tin điện tử Tỉnh Sơn La
If You Invested $1,000 in Enlivex Ltd (ENLV) - Stock Titan
Volume Recap: Is now the right time to enter Enlivex Therapeutics Ltd2026 Earnings Impact & Community Consensus Stock Picks - baoquankhu1.vn
ENLV SEC FilingsEnlivex Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Enlivex Shares Tokenized on Ondo Global Markets to Expand Global Digital Investor Access - The Globe and Mail
Ondo Global Markets Tokenizes Enlivex’s Ordinary Shares - The Manila Times
Ondo tokenizes Enlivex (Nasdaq: ENLV) shares for global digital access - Stock Titan
Ondo Global Markets Tokenizes Enlivex's Ordinary Shares - 富途牛牛
Rain Crypto Jump On Red Market: Big Pharma Enlivex Raised $21M Treasury - 99Bitcoins
ENLV Stock Rating: HC Wainwright & Co. Raises Price Target to $2 - GuruFocus
Enlivex shares jump after earnings as treasury gains boost results - MSN
ENLV Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ENLV PE Ratio & Valuation, Is ENLV Overvalued - Intellectia AI
Enlivex Ltd Stock (ENLV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):